On 04 April 2022, Telix Pharmaceuticals Limited (ASX: TLX) announced that it is part AU$71.2 million Australian Precision Medicine Enterprise (APME) Project, which has been given AU$23 million in Federal Government grant funding under the Manufacturing Collaboration Stream of the Modern Manufacturing Initiative.
The APME Project unite industry partners Global Medical Solutions’ Australia subsidiary, Global Medical Solutions Australia and Telix Pharmaceuticals with Monash University to address the Good Manufacturing Practice gap in the Australian radiopharmaceuticals manufacturing sector.
The project will assist extensive innovative development and manufacturing of precision medicines and theranostics for the Australian and APAC markets, with business-to-business and business-to-research collaboration (University and Industry) at its core.
Being a project partner, Telix will benefit from the improved capacity to develop & manufacture theranostic radiopharmaceuticals in Australia, firming up its global supply chain for clinical as well as commercial products.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Suite 1A, Level 2, 802-808 Pacific Highway, Gordon NSW 2072, Australia | 1800 005 780 | info@kapitales.com.au
Oct 16, 2024
Oct 16, 2024
Oct 16, 2024
Oct 15, 2024
Oct 15, 2024
Oct 15, 2024
Oct 14, 2024
Oct 14, 2024
Oct 14, 2024
Oct 10, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
